The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Skin Cancer Diagnostics and Therapeutics-Global Market Insights and Sales Trends 2025
Synopsis
On the basis of the type of tissue affected, there are three major types of skin cancer, namely, basal cell carcinoma, squamous-cell carcinoma, and melanoma. Factors such as increasing incidences of skin cancer, favorable government initiatives, the development of novel immunotherapies, and the extension of current therapies are fueling the growth of the market. However, high cost associated with therapy, a stringent regulatory environment, and the lack of awareness in the general population could adversely affect market growth.
The global Skin Cancer Diagnostics and Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Skin Cancer Diagnostics and Therapeutics in various end use industries. The expanding demands from the Hospital, Clinic, Cancer Research Center and Others, are propelling Skin Cancer Diagnostics and Therapeutics market. Basal Cell Carcinoma, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Squamous Cell Carcinoma segment is estimated at % CAGR for the next seven-year period.
In 2017, North America was the largest regional market, in terms of revenue. The high prevalence of skin cancer and its risk factors, a favorable reimbursement environment, and high adoption rate of novel technologies are primary factors behind the large market size. The Asia-Pacific region is expected to grow at a rapid pace over the forecast period, owing to increasing healthcare expenditure and government initiatives aimed at increasing awareness in the developing economies of the region.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Skin Cancer Diagnostics and Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Skin Cancer Diagnostics and Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Skin Cancer Diagnostics and Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Skin Cancer Diagnostics and Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Skin Cancer Diagnostics and Therapeutics covered in this report include GlaxoSmithKline, Merck, Novartis, Pfizer, Qiagen, Roche, Sanofi, Abbott and AstraZeneca, etc.
The global Skin Cancer Diagnostics and Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Merck
Novartis
Pfizer
Qiagen
Roche
Sanofi
Abbott
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Global Skin Cancer Diagnostics and Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Skin Cancer Diagnostics and Therapeutics market, Segment by Type:
Basal Cell Carcinoma
Squamous Cell Carcinoma
Melanoma
Global Skin Cancer Diagnostics and Therapeutics market, by Application
Hospital
Clinic
Cancer Research Center
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Skin Cancer Diagnostics and Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
On the basis of the type of tissue affected, there are three major types of skin cancer, namely, basal cell carcinoma, squamous-cell carcinoma, and melanoma. Factors such as increasing incidences of skin cancer, favorable government initiatives, the development of novel immunotherapies, and the extension of current therapies are fueling the growth of the market. However, high cost associated with therapy, a stringent regulatory environment, and the lack of awareness in the general population could adversely affect market growth.
The global Skin Cancer Diagnostics and Therapeutics market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of Skin Cancer Diagnostics and Therapeutics in various end use industries. The expanding demands from the Hospital, Clinic, Cancer Research Center and Others, are propelling Skin Cancer Diagnostics and Therapeutics market. Basal Cell Carcinoma, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Squamous Cell Carcinoma segment is estimated at % CAGR for the next seven-year period.
In 2017, North America was the largest regional market, in terms of revenue. The high prevalence of skin cancer and its risk factors, a favorable reimbursement environment, and high adoption rate of novel technologies are primary factors behind the large market size. The Asia-Pacific region is expected to grow at a rapid pace over the forecast period, owing to increasing healthcare expenditure and government initiatives aimed at increasing awareness in the developing economies of the region.
Report Objectives
This report provides market insight on the different segments, by players, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for Skin Cancer Diagnostics and Therapeutics, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global Skin Cancer Diagnostics and Therapeutics market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global Skin Cancer Diagnostics and Therapeutics market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, Skin Cancer Diagnostics and Therapeutics sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of Skin Cancer Diagnostics and Therapeutics covered in this report include GlaxoSmithKline, Merck, Novartis, Pfizer, Qiagen, Roche, Sanofi, Abbott and AstraZeneca, etc.
The global Skin Cancer Diagnostics and Therapeutics market report caters to various stakeholders in this industry including investors, suppliers, product players, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GlaxoSmithKline
Merck
Novartis
Pfizer
Qiagen
Roche
Sanofi
Abbott
AstraZeneca
Bristol-Myers Squibb
Eli Lilly
Global Skin Cancer Diagnostics and Therapeutics market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Skin Cancer Diagnostics and Therapeutics market, Segment by Type:
Basal Cell Carcinoma
Squamous Cell Carcinoma
Melanoma
Global Skin Cancer Diagnostics and Therapeutics market, by Application
Hospital
Clinic
Cancer Research Center
Others
Core Chapters
Chapter One: Introduces the report scope of the report, executive summary of global and regional market size and CAGR for the history and forecast period (2018-2023, 2024-2029). It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter Two: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter Three: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter Four: Detailed analysis of Skin Cancer Diagnostics and Therapeutics companies’ competitive landscape, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Five: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product introduction, revenue, recent development, etc.
Chapter Six, Seven, Eight, Nine and Ten: North America, Europe, Asia Pacific, Latin America, Middle East & Africa, revenue by country.
Chapter Eleven: this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Research Finding/Conclusion
Index1 Market Overview of Skin Cancer Diagnostics and Therapeutics
1.1 Skin Cancer Diagnostics and Therapeutics Market Overview
1.1.1 Skin Cancer Diagnostics and Therapeutics Product Scope
1.1.2 Skin Cancer Diagnostics and Therapeutics Market Status and Outlook
1.2 Global Skin Cancer Diagnostics and Therapeutics Market Size Overview by Region 2018 VS 2022 VS 2029
1.3 Global Skin Cancer Diagnostics and Therapeutics Market Size by Region (2018-2029)
1.4 Global Skin Cancer Diagnostics and Therapeutics Historic Market Size by Region (2018-2023)
1.5 Global Skin Cancer Diagnostics and Therapeutics Market Size Forecast by Region (2024-2029)
1.6 Key Regions, Skin Cancer Diagnostics and Therapeutics Market Size (2018-2029)
1.6.1 North America Skin Cancer Diagnostics and Therapeutics Market Size (2018-2029)
1.6.2 Europe Skin Cancer Diagnostics and Therapeutics Market Size (2018-2029)
1.6.3 Asia-Pacific Skin Cancer Diagnostics and Therapeutics Market Size (2018-2029)
1.6.4 Latin America Skin Cancer Diagnostics and Therapeutics Market Size (2018-2029)
1.6.5 Middle East & Africa Skin Cancer Diagnostics and Therapeutics Market Size (2018-2029)
2 Skin Cancer Diagnostics and Therapeutics Market by Type
2.1 Introduction
2.1.1 Basal Cell Carcinoma
2.1.2 Squamous Cell Carcinoma
2.1.3 Melanoma
2.2 Global Skin Cancer Diagnostics and Therapeutics Market Size by Type: 2018 VS 2022 VS 2029
2.2.1 Global Skin Cancer Diagnostics and Therapeutics Historic Market Size by Type (2018-2023)
2.2.2 Global Skin Cancer Diagnostics and Therapeutics Forecasted Market Size by Type (2024-2029)
2.3 Key Regions Market Size by Type
2.3.1 North America Skin Cancer Diagnostics and Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.2 Europe Skin Cancer Diagnostics and Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.3 Asia-Pacific Skin Cancer Diagnostics and Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.4 Latin America Skin Cancer Diagnostics and Therapeutics Revenue Breakdown by Type (2018-2029)
2.3.5 Middle East and Africa Skin Cancer Diagnostics and Therapeutics Revenue Breakdown by Type (2018-2029)
3 Skin Cancer Diagnostics and Therapeutics Market Overview by Application
3.1 Introduction
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Cancer Research Center
3.1.4 Others
3.2 Global Skin Cancer Diagnostics and Therapeutics Market Size by Application: 2018 VS 2022 VS 2029
3.2.1 Global Skin Cancer Diagnostics and Therapeutics Historic Market Size by Application (2018-2023)
3.2.2 Global Skin Cancer Diagnostics and Therapeutics Forecasted Market Size by Application (2024-2029)
3.3 Key Regions Market Size by Application
3.3.1 North America Skin Cancer Diagnostics and Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.2 Europe Skin Cancer Diagnostics and Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.3 Asia-Pacific Skin Cancer Diagnostics and Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.4 Latin America Skin Cancer Diagnostics and Therapeutics Revenue Breakdown by Application (2018-2029)
3.3.5 Middle East and Africa Skin Cancer Diagnostics and Therapeutics Revenue Breakdown by Application (2018-2029)
4 Skin Cancer Diagnostics and Therapeutics Competition Analysis by Players
4.1 Global Skin Cancer Diagnostics and Therapeutics Market Size by Players (2018-2023)
4.2 Global Top Players by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in Skin Cancer Diagnostics and Therapeutics as of 2022)
4.3 Date of Key Players Enter into Skin Cancer Diagnostics and Therapeutics Market
4.4 Global Top Players Skin Cancer Diagnostics and Therapeutics Headquarters and Area Served
4.5 Key Players Skin Cancer Diagnostics and Therapeutics Product Solution and Service
4.6 Competitive Status
4.6.1 Skin Cancer Diagnostics and Therapeutics Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles
5.1 GlaxoSmithKline
5.1.1 GlaxoSmithKline Profile
5.1.2 GlaxoSmithKline Main Business
5.1.3 GlaxoSmithKline Skin Cancer Diagnostics and Therapeutics Products, Services and Solutions
5.1.4 GlaxoSmithKline Skin Cancer Diagnostics and Therapeutics Revenue (US$ Million) & (2018-2023)
5.1.5 GlaxoSmithKline Recent Developments
5.2 Merck
5.2.1 Merck Profile
5.2.2 Merck Main Business
5.2.3 Merck Skin Cancer Diagnostics and Therapeutics Products, Services and Solutions
5.2.4 Merck Skin Cancer Diagnostics and Therapeutics Revenue (US$ Million) & (2018-2023)
5.2.5 Merck Recent Developments
5.3 Novartis
5.3.1 Novartis Profile
5.3.2 Novartis Main Business
5.3.3 Novartis Skin Cancer Diagnostics and Therapeutics Products, Services and Solutions
5.3.4 Novartis Skin Cancer Diagnostics and Therapeutics Revenue (US$ Million) & (2018-2023)
5.3.5 Pfizer Recent Developments
5.4 Pfizer
5.4.1 Pfizer Profile
5.4.2 Pfizer Main Business
5.4.3 Pfizer Skin Cancer Diagnostics and Therapeutics Products, Services and Solutions
5.4.4 Pfizer Skin Cancer Diagnostics and Therapeutics Revenue (US$ Million) & (2018-2023)
5.4.5 Pfizer Recent Developments
5.5 Qiagen
5.5.1 Qiagen Profile
5.5.2 Qiagen Main Business
5.5.3 Qiagen Skin Cancer Diagnostics and Therapeutics Products, Services and Solutions
5.5.4 Qiagen Skin Cancer Diagnostics and Therapeutics Revenue (US$ Million) & (2018-2023)
5.5.5 Qiagen Recent Developments
5.6 Roche
5.6.1 Roche Profile
5.6.2 Roche Main Business
5.6.3 Roche Skin Cancer Diagnostics and Therapeutics Products, Services and Solutions
5.6.4 Roche Skin Cancer Diagnostics and Therapeutics Revenue (US$ Million) & (2018-2023)
5.6.5 Roche Recent Developments
5.7 Sanofi
5.7.1 Sanofi Profile
5.7.2 Sanofi Main Business
5.7.3 Sanofi Skin Cancer Diagnostics and Therapeutics Products, Services and Solutions
5.7.4 Sanofi Skin Cancer Diagnostics and Therapeutics Revenue (US$ Million) & (2018-2023)
5.7.5 Sanofi Recent Developments
5.8 Abbott
5.8.1 Abbott Profile
5.8.2 Abbott Main Business
5.8.3 Abbott Skin Cancer Diagnostics and Therapeutics Products, Services and Solutions
5.8.4 Abbott Skin Cancer Diagnostics and Therapeutics Revenue (US$ Million) & (2018-2023)
5.8.5 Abbott Recent Developments
5.9 AstraZeneca
5.9.1 AstraZeneca Profile
5.9.2 AstraZeneca Main Business
5.9.3 AstraZeneca Skin Cancer Diagnostics and Therapeutics Products, Services and Solutions
5.9.4 AstraZeneca Skin Cancer Diagnostics and Therapeutics Revenue (US$ Million) & (2018-2023)
5.9.5 AstraZeneca Recent Developments
5.10 Bristol-Myers Squibb
5.10.1 Bristol-Myers Squibb Profile
5.10.2 Bristol-Myers Squibb Main Business
5.10.3 Bristol-Myers Squibb Skin Cancer Diagnostics and Therapeutics Products, Services and Solutions
5.10.4 Bristol-Myers Squibb Skin Cancer Diagnostics and Therapeutics Revenue (US$ Million) & (2018-2023)
5.10.5 Bristol-Myers Squibb Recent Developments
5.11 Eli Lilly
5.11.1 Eli Lilly Profile
5.11.2 Eli Lilly Main Business
5.11.3 Eli Lilly Skin Cancer Diagnostics and Therapeutics Products, Services and Solutions
5.11.4 Eli Lilly Skin Cancer Diagnostics and Therapeutics Revenue (US$ Million) & (2018-2023)
5.11.5 Eli Lilly Recent Developments
6 North America
6.1 North America Skin Cancer Diagnostics and Therapeutics Market Size by Country (2018-2029)
6.2 U.S.
6.3 Canada
7 Europe
7.1 Europe Skin Cancer Diagnostics and Therapeutics Market Size by Country (2018-2029)
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic Countries
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific Skin Cancer Diagnostics and Therapeutics Market Size by Region (2018-2029)
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America Skin Cancer Diagnostics and Therapeutics Market Size by Country (2018-2029)
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa Skin Cancer Diagnostics and Therapeutics Market Size by Country (2018-2029)
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 Skin Cancer Diagnostics and Therapeutics Market Dynamics
11.1 Skin Cancer Diagnostics and Therapeutics Industry Trends
11.2 Skin Cancer Diagnostics and Therapeutics Market Drivers
11.3 Skin Cancer Diagnostics and Therapeutics Market Challenges
11.4 Skin Cancer Diagnostics and Therapeutics Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
